Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvo Research and Paladin Labs have announced that the Health Canada has approved a new dosing regimen for Pennsaid. Paladin sells and markets Pennsaid in Canada, having acquired exclusive Canadian Pennsaid rights from Nuvo in August 2005.
Subscribe to our email newsletter
The new dosing regimen of Pennsaid will be 50 drops per knee, three times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, four times a day. According to the company, Pennsaid is now the only topical NSAID approved in Canada with this new improved dosing regimen.
Henrich Guntermann, Nuvo’s president and CEO, said: “The new improved dosing regimen of Pennsaid is a significant clinical advantage. We are eager to replicate Pennsaid’s Canadian success in the US market and continue to work diligently on obtaining FDA approval.”